

# Don't Skip the Forearm

WavelinQ™ EndoAVF System offers two additional forearm AV fistula creation sites, with split outflow, enabling multiple cannulation zones.<sup>3</sup>

6X  
FEWER

post-creation  
interventions per  
patient year<sup>1</sup>

ONLY  
16%

of pre-dialysis patients with a  
WavelinQ™ EndoAVF initiated  
dialysis with a CVC<sup>2</sup>

The WavelinQ™ EndoAVF System uses two thin, flexible, magnetic catheters and a burst of RF energy to create an endovascular AV fistula.

## WavelinQ™

EndoAVF System



[bd.com](http://bd.com) BD, Tempe, AZ, USA, 1 800 321 4254

<sup>1</sup> Yang S, Arnold R, Lok C, Rajan D, Glickman M. J Vasc Access 2017; 18(Suppl. 2): 8-14. As demonstrated with the WavelinQ™ 6F EndoAVF System compared to a propensity-score matched surgical AVF cohort, comprised of a 5% CMS sample of claims data. N=60 for each. Total Intervention Rate of 3.4 versus 0.6, respectively.

<sup>2</sup> Clinical WavelinQ™ 4F EndoAVF System data on file. N=4/25 pre-dialysis patients initiated dialysis on a CVC at 6 months.

<sup>3</sup> Compared to surgical AVF creation

The WavelinQ™ EndoAVF System is indicated for the creation of an arteriovenous fistula (AVF) using concomitant ulnar artery and ulnar vein or concomitant radial artery and radial vein in patients with minimum artery and vein diameters of 2.0 mm at the fistula creation site who have chronic kidney disease and need hemodialysis. The WavelinQ™ System is contraindicated in target vessels < 2mm in diameter.

The WavelinQ™ System should not be used in patients who have (i) known central venous stenosis or upper extremity venous occlusion on the same side as the planned AVF creation, (ii) a known allergy or reaction to any drugs/fluids used in this procedure, or (iii) known adverse reactions to moderate sedation and/or anesthesia. The known potential risks related to the WavelinQ™ System and procedure, a standard AVF, and endovascular procedures may include but are not limited to: aborted or longer procedure; additional procedures; bleeding, hematoma or hemorrhage; bruising; burns; death; electrocution; embolism; failure to mature; fever; increased risk of congestive heart failure; infection; numbness, tingling and/or coolness; occlusion/stenosis; problem due to sedation or anesthesia; pseudoaneurysm; sepsis; steal or ischemia; swelling, irritation, or pain; thrombosis; toxic or allergic reaction; venous hypertension (arm swelling); vessel, nerve, or AVF damage or rupture; wound problem. **Please consult product labels and instructions for use for indications, contraindications, hazards, warnings and precautions.** BD, the BD Logo, and WavelinQ are trademarks of Becton, Dickinson and Company or its affiliates. © 2022 BD. All Rights Reserved. © 2022 Illustration by Mike Austin BD-15527v2